Cargando…
The impact of tumor metabolic activity assessed by (18)F-FET amino acid PET imaging in particle radiotherapy of high-grade glioma patients
BACKGROUND: Selective uptake of (18)F-fluoro-ethyl-tyrosine ((18)F-FET) is used in high-grade glioma (HGG) to assess tumor metabolic activity via positron emission tomography (PET). We aim to investigate its value for target volume definition, as a prognosticator, and associations with whole-blood t...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531169/ https://www.ncbi.nlm.nih.gov/pubmed/36203443 http://dx.doi.org/10.3389/fonc.2022.901390 |
_version_ | 1784801845484453888 |
---|---|
author | Waltenberger, Maria Furkel, Jennifer Röhrich, Manuel Salome, Patrick Debus, Charlotte Tawk, Bouchra Gahlawat, Aoife Ward Kudak, Andreas Dostal, Matthias Wirkner, Ute Schwager, Christian Herold-Mende, Christel Combs, Stephanie E. König, Laila Debus, Jürgen Haberkorn, Uwe Abdollahi, Amir Knoll, Maximilian |
author_facet | Waltenberger, Maria Furkel, Jennifer Röhrich, Manuel Salome, Patrick Debus, Charlotte Tawk, Bouchra Gahlawat, Aoife Ward Kudak, Andreas Dostal, Matthias Wirkner, Ute Schwager, Christian Herold-Mende, Christel Combs, Stephanie E. König, Laila Debus, Jürgen Haberkorn, Uwe Abdollahi, Amir Knoll, Maximilian |
author_sort | Waltenberger, Maria |
collection | PubMed |
description | BACKGROUND: Selective uptake of (18)F-fluoro-ethyl-tyrosine ((18)F-FET) is used in high-grade glioma (HGG) to assess tumor metabolic activity via positron emission tomography (PET). We aim to investigate its value for target volume definition, as a prognosticator, and associations with whole-blood transcriptome liquid biopsy (WBT lbx) for which we recently reported feasibility to mirror tumor characteristics and response to particle irradiation in recurrent HGG (rHGG). METHODS: (18)F-FET-PET data from n = 43 patients with primary glioblastoma (pGBM) and n = 33 patients with rHGG were assessed. pGBM patients were irradiated with photons and sequential proton/carbon boost, and rHGG patients were treated with carbon re-irradiation (CIR). WBT (Illumina HumanHT-12 Expression BeadChips) lbx was available for n = 9 patients from the rHGG cohort. PET isocontours (40%–70% SUVmax, 10% steps) and MRI-based treatment volumes (MRIvol) were compared using the conformity index (CI) (pGBM, n = 16; rHGG, n = 27). Associations with WBT lbx data were tested on gene expression level and inferred pathways activity scores (PROGENy) and from transcriptome estimated cell fractions (CIBERSORT, xCell). RESULTS: In pGBM, median SUVmax was higher in PET acquired pre-radiotherapy (4.1, range (R) 1.5–7.8; n = 20) vs. during radiotherapy (3.3, R 1.5–5.7, n = 23; p = 0.03) and in non-resected (4.7, R 2.9–7.9; n = 11) vs. resected tumors (3.3, R 1.5–7.8, n = 32; p = 0.01). In rHGG, a trend toward higher SUVmax values in grade IV tumors was observed (p = 0.13). Median MRIvol was 32.34 (R 8.75–108.77) cm(3) in pGBM (n = 16) and 20.77 (R 0.63–128.44) cm(3) in rHGG patients (n = 27). The highest median CI was observed for 40% (pGBM, 0.31) and 50% (rHGG, 0.43, all tumors) isodose, with 70% (40%) isodose in grade III (IV) rHGG tumors (median CI, 0.38 and 0.49). High SUVmax was linked to shorter survival in pGBM (>3.3, p = 0.001, OR 6.0 [2.1–17.4]) and rHGG (>2.8, p = 0.02, OR 4.1 [1.2–13.9]). SUVmax showed associations with inferred monocyte fractions, hypoxia, and TGFbeta pathway activity and links to immune checkpoint gene expression from WBT lbx. CONCLUSION: The benefits of (18)F-FET-PET imaging on gross tumor volume (GTV) definition for particle radiotherapy warrant further evaluation. SUVmax might assist in prognostic stratification of HGG patients for particle radiotherapy, highlights heterogeneity in rHGG, and is positively associated with unfavorable signatures in peripheral whole-blood transcriptomes. |
format | Online Article Text |
id | pubmed-9531169 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-95311692022-10-05 The impact of tumor metabolic activity assessed by (18)F-FET amino acid PET imaging in particle radiotherapy of high-grade glioma patients Waltenberger, Maria Furkel, Jennifer Röhrich, Manuel Salome, Patrick Debus, Charlotte Tawk, Bouchra Gahlawat, Aoife Ward Kudak, Andreas Dostal, Matthias Wirkner, Ute Schwager, Christian Herold-Mende, Christel Combs, Stephanie E. König, Laila Debus, Jürgen Haberkorn, Uwe Abdollahi, Amir Knoll, Maximilian Front Oncol Oncology BACKGROUND: Selective uptake of (18)F-fluoro-ethyl-tyrosine ((18)F-FET) is used in high-grade glioma (HGG) to assess tumor metabolic activity via positron emission tomography (PET). We aim to investigate its value for target volume definition, as a prognosticator, and associations with whole-blood transcriptome liquid biopsy (WBT lbx) for which we recently reported feasibility to mirror tumor characteristics and response to particle irradiation in recurrent HGG (rHGG). METHODS: (18)F-FET-PET data from n = 43 patients with primary glioblastoma (pGBM) and n = 33 patients with rHGG were assessed. pGBM patients were irradiated with photons and sequential proton/carbon boost, and rHGG patients were treated with carbon re-irradiation (CIR). WBT (Illumina HumanHT-12 Expression BeadChips) lbx was available for n = 9 patients from the rHGG cohort. PET isocontours (40%–70% SUVmax, 10% steps) and MRI-based treatment volumes (MRIvol) were compared using the conformity index (CI) (pGBM, n = 16; rHGG, n = 27). Associations with WBT lbx data were tested on gene expression level and inferred pathways activity scores (PROGENy) and from transcriptome estimated cell fractions (CIBERSORT, xCell). RESULTS: In pGBM, median SUVmax was higher in PET acquired pre-radiotherapy (4.1, range (R) 1.5–7.8; n = 20) vs. during radiotherapy (3.3, R 1.5–5.7, n = 23; p = 0.03) and in non-resected (4.7, R 2.9–7.9; n = 11) vs. resected tumors (3.3, R 1.5–7.8, n = 32; p = 0.01). In rHGG, a trend toward higher SUVmax values in grade IV tumors was observed (p = 0.13). Median MRIvol was 32.34 (R 8.75–108.77) cm(3) in pGBM (n = 16) and 20.77 (R 0.63–128.44) cm(3) in rHGG patients (n = 27). The highest median CI was observed for 40% (pGBM, 0.31) and 50% (rHGG, 0.43, all tumors) isodose, with 70% (40%) isodose in grade III (IV) rHGG tumors (median CI, 0.38 and 0.49). High SUVmax was linked to shorter survival in pGBM (>3.3, p = 0.001, OR 6.0 [2.1–17.4]) and rHGG (>2.8, p = 0.02, OR 4.1 [1.2–13.9]). SUVmax showed associations with inferred monocyte fractions, hypoxia, and TGFbeta pathway activity and links to immune checkpoint gene expression from WBT lbx. CONCLUSION: The benefits of (18)F-FET-PET imaging on gross tumor volume (GTV) definition for particle radiotherapy warrant further evaluation. SUVmax might assist in prognostic stratification of HGG patients for particle radiotherapy, highlights heterogeneity in rHGG, and is positively associated with unfavorable signatures in peripheral whole-blood transcriptomes. Frontiers Media S.A. 2022-09-20 /pmc/articles/PMC9531169/ /pubmed/36203443 http://dx.doi.org/10.3389/fonc.2022.901390 Text en Copyright © 2022 Waltenberger, Furkel, Röhrich, Salome, Debus, Tawk, Gahlawat, Kudak, Dostal, Wirkner, Schwager, Herold-Mende, Combs, König, Debus, Haberkorn, Abdollahi and Knoll https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Waltenberger, Maria Furkel, Jennifer Röhrich, Manuel Salome, Patrick Debus, Charlotte Tawk, Bouchra Gahlawat, Aoife Ward Kudak, Andreas Dostal, Matthias Wirkner, Ute Schwager, Christian Herold-Mende, Christel Combs, Stephanie E. König, Laila Debus, Jürgen Haberkorn, Uwe Abdollahi, Amir Knoll, Maximilian The impact of tumor metabolic activity assessed by (18)F-FET amino acid PET imaging in particle radiotherapy of high-grade glioma patients |
title | The impact of tumor metabolic activity assessed by (18)F-FET amino acid PET imaging in particle radiotherapy of high-grade glioma patients |
title_full | The impact of tumor metabolic activity assessed by (18)F-FET amino acid PET imaging in particle radiotherapy of high-grade glioma patients |
title_fullStr | The impact of tumor metabolic activity assessed by (18)F-FET amino acid PET imaging in particle radiotherapy of high-grade glioma patients |
title_full_unstemmed | The impact of tumor metabolic activity assessed by (18)F-FET amino acid PET imaging in particle radiotherapy of high-grade glioma patients |
title_short | The impact of tumor metabolic activity assessed by (18)F-FET amino acid PET imaging in particle radiotherapy of high-grade glioma patients |
title_sort | impact of tumor metabolic activity assessed by (18)f-fet amino acid pet imaging in particle radiotherapy of high-grade glioma patients |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9531169/ https://www.ncbi.nlm.nih.gov/pubmed/36203443 http://dx.doi.org/10.3389/fonc.2022.901390 |
work_keys_str_mv | AT waltenbergermaria theimpactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT furkeljennifer theimpactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT rohrichmanuel theimpactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT salomepatrick theimpactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT debuscharlotte theimpactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT tawkbouchra theimpactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT gahlawataoifeward theimpactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT kudakandreas theimpactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT dostalmatthias theimpactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT wirknerute theimpactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT schwagerchristian theimpactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT heroldmendechristel theimpactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT combsstephaniee theimpactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT koniglaila theimpactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT debusjurgen theimpactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT haberkornuwe theimpactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT abdollahiamir theimpactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT knollmaximilian theimpactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT waltenbergermaria impactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT furkeljennifer impactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT rohrichmanuel impactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT salomepatrick impactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT debuscharlotte impactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT tawkbouchra impactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT gahlawataoifeward impactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT kudakandreas impactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT dostalmatthias impactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT wirknerute impactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT schwagerchristian impactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT heroldmendechristel impactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT combsstephaniee impactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT koniglaila impactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT debusjurgen impactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT haberkornuwe impactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT abdollahiamir impactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients AT knollmaximilian impactoftumormetabolicactivityassessedby18ffetaminoacidpetimaginginparticleradiotherapyofhighgradegliomapatients |